acitretin / Generic mfg. - LARVOL DELTA

Clinicopathological and management outcome in 70 patients with pityriasis rubra pilaris: A retrospective analysis. (PubMed, Indian J Dermatol Venereol Leprol) - "Oral retinoids, especially acitretin, were the most preferred and effective treatment. Five patients showed improvement with methotrexate and two needed biological agents...Conclusion PRP is still a rare, difficult-to-manage disease. More studies are required to standardise and improve the diagnosis and treatment approaches for the disease."

Journal • Retrospective data • Dermatology • Dermatopathology • Rare Diseases

Cardiovascular safety of systemic psoriasis treatments: A prospective cohort study in the BIOBADADERM registry. (PubMed, J Eur Acad Dermatol Venereol) - "This real-world evidence study indicates a potential association between APR and IL-17 with a lower incidence of MACE, while CYC showed a higher incidence compared to MTX. These findings underscore the importance of considering cardiovascular outcomes when selecting systemic therapies for patients with psoriasis."

Journal • Cardiovascular • Dermatology • Immunology • Inflammation • Psoriasis • IL12A • IL17A • IL23A

Successful treatment of generalized pustular psoriasis with chronic hepatitis B using spesolimab: A case report. (PubMed, Medicine (Baltimore)) - "Our study shows that spesolimab could be employed as a safe and effective therapeutic option for patients with GPP and other underlying conditions."

Journal • Dermatology • Hepatitis B • Hepatology • Immunology • Infectious Disease • Inflammation • Liver Failure • Psoriasis • Pustular Psoriasis

Poikiloderma With Neutropenia due to Novel USB1 Mutation. (PubMed, Pediatr Dermatol) - "We present a 17-year-old male with a novel USB1 gene mutation (c.368T>C [p.Leu123Pro]), who exhibited typical dermatological features, including poikiloderma, nail thickening, and calcinosis cutis, in addition to hypogonadism. This case highlights the broad clinical spectrum of PN and the need for comprehensive care and surveillance."

Journal • Dermatology • Endocrine Disorders • Hematological Disorders • Infectious Disease • Metabolic Disorders • Neutropenia • Oncology

Hypertrophic lupus erythematosus hypertrophic lichen planus overlap responding to acitretin and anifrolumab. (PubMed, JAAD Case Rep) - No abstract available

Journal • Cutaneous Lupus Erythematosus • Dermatology • Dermatopathology • Immunology • Inflammatory Arthritis • Lichen Planus • Lupus

Clinical Responses and Transcriptomic Analysis of Spesolimab in a Girl With Severe Dermatitis, Multiple Allergies and Metabolic Wasting Syndrome. (PubMed, Exp Dermatol) - "Previous studies have demonstrated that acitretin and systemic biologics targeting IL-17, IL-12/IL-23, and IL-4 are effective in treating SAM syndrome. This case highlights the therapeutic potential of targeting the IL-36 pathway in SAM syndrome and supports the use of skin RNA-seq for personalised selection of anti-inflammatory biologics in rare dermatological disorders. This report marks the first clinical application of Spesolimab in SAM syndrome, offering a novel therapeutic approach."

Journal • Allergy • Cachexia • Dermatitis • Dermatology • Genetic Disorders • Immunology • Infectious Disease • Psoriasis • Pustular Psoriasis • IL12A • IL17A • IL23A • IL4

Modulating the NLRP3 Inflammasome: Acitretin as a potential treatment for Sepsis-induced acute lung injury. (PubMed, Int Immunopharmacol) - "Acitretin demonstrated significant anti-inflammatory properties through the suppression of the NLRP3 inflammasome, suggesting its potential as a therapeutic strategy for sepsis and related complications."

Journal • Acute Lung Injury • Dermatology • Immunology • Infectious Disease • Inflammation • Psoriasis • Respiratory Diseases • Septic Shock • IL1B • NLRP3

Possible ruxolitinib-associated acquired epidermodysplasia verruciformis and skin cancers: a case report (EADO-WCM 2025) - "The patient had a history of nonmelanoma skin cancers (NMSCs) and viral warts, previously treated with cryotherapy, topical imiquimod, and surgeries...Acitretin initiation and HPV vaccination were under consideration but have not yet been implemented, as the patient initially received care outside the authors' institution...Its immunosuppressive effects may predispose patients to HPV-related conditions and skin malignancies. Advances in HPV typing and gene sequencing may further aid in identifying AEV lesions with a higher risk of progression to SCC."

Case report • Clinical • Basal Cell Carcinoma • Dermatology • Genetic Disorders • Non-melanoma Skin Cancer • Polycythemia Vera • Skin Cancer • Solid Tumor • Squamous Cell Carcinoma • Squamous Cell Skin Cancer

Association of Obesity and Innate Immune Markers With Resistance to Biologic Therapy in Psoriasis. (PubMed, JAMA Dermatol) - "A cross-sectional study was carried out including patients aged 18 years or older who visited the Gachon University Gil Medical Center dermatology clinic between January 2012 and December 2022 with plaque-type severe psoriasis with a Psoriasis Area and Severity Index score greater than 10 and body surface area larger than 10 despite conventional treatment with cyclosporine, methotrexate, acitretin, and phototherapy for longer than 3 months, and treatment with biologics for at least 24 months. This cross-sectional study found that dysregulated innate immune responses in the epidermis and heightened neutrophil activity may be responsible for decreased sustainability of therapeutic responses to biologics. Given that current biologics mainly target dermal adaptive immune-related mediators, the development of novel therapeutic strategies to target the epidermal innate immune response, including neutrophils, is warranted."

Journal • Dermatology • Genetic Disorders • Immunology • Obesity • Oncology • Psoriasis • CXCL8 • IL17A • IL1R1 • IL23A • LCN2 • S100A8 • S100A9 • TNFA • TNFSF10

Epidemiological, Genetic, Clinical, and Treatment Differences of Generalized Pustular Psoriasis and Acrodermatitis Continua of Hallopeau Across Ethnicities: A Systematic Review. (PubMed, Am J Clin Dermatol) - "This systematic review underscores notable ethnic differences in genetic profiles, clinical features, and therapeutic responses in GPP and ACH. The diagnosis of GPP and ACH may differ across studies and the true impacts of ethnicities on these differences remain to be confirmed. Nonetheless, the results from this study enhance our understanding of the heterogeneous characteristics of GPP and ACH, highlighting the necessity of incorporating ethnic differences into the diagnosis, genetic testing, and management strategies for patients with GPP and ACH."

Journal • Review • Dermatitis • Dermatology • Immunology • Psoriasis • Pustular Psoriasis

Apolipoproteins in Psoriasis: The Effect of Acitretin Treatment and UVB Phototherapy. (PubMed, Metabolites) - "The results of this study confirm the presence of metabolic disturbances in psoriatic patients. The treatment with NB-UVB or acitretin did not cause any significant changes in the apolipoproteins profile. Thus, we found no detrimental impact of acitretin on the apolipoproteins profile, despite the observed rise in total cholesterol concentration after the treatment. Further research is needed to explore whether specific therapeutic approaches can modify these disturbances and potentially improve long-term cardiovascular outcomes in this population."

Journal • Cardiovascular • Dermatology • Immunology • Inflammation • Metabolic Disorders • Psoriasis • APOA1 • APOA2 • APOC1 • APOD • APOE • CLU • CRP

Analysis of the therapeutic effect of acitretin capsules combined with cooling blood and detoxifying formula on psoriasis hemorrhagic fever and its impact on the gut microbiota of patients. (PubMed, Medicine (Baltimore)) - "The EG also showed a significant increase in GM diversity after treatment (P < .05). Acitretin capsules combined with the CBDF is effective in treating psoriasis hemorrhagic fever and positively affects the GM, offering a potential new treatment approach."

Journal • Dermatology • Hematological Disorders • Immunology • Inflammation • Psoriasis • IL2 • IL6

Brodalumab for Darier Disease: A Case Series Highlighting IL-17 Inhibition as a Potential Treatment. (PubMed, Int J Dermatol) - No abstract available

Journal • IL17A

Comparative Analysis of Sociodemographic, Clinical Features, Laboratory Findings, and Treatment Protocols in Generalized and Localized Cutaneous Lichen Planus. (PubMed, Cureus) - "Narrowband ultraviolet B and acitretin were more effective in treating patients with GCLP (p<0.001 and p=0.001, respectively). When the relapse rates in both LP groups were compared, relapses were more frequent in the patients with GCLP (p=0.022).  The lesion localization, treatment needs, and relapse rates of patients with GCLP differ from those of patients with LCLP.  This article was previously presented as an e-poster at the 32nd National Turkish Dermatology Congress on November 24, 2024."

Journal • Dermatology • Dermatopathology • Dyslipidemia • Hepatitis B • Hepatology • Hypertriglyceridemia • Infectious Disease • Inflammation • Lichen Planus • Pruritus

Lessons learned from the COAST (Contemporary Outcomes After cutaneous SCC in Transplant recipients) study: management and outcomes following the first cutaneous squamous cell carcinoma in kidney transplant recipients (EADO-WCM 2025) - "Within 6 months of a first CSCC, 6% started systemic chemoprevention (acitretin/nicotinamide), 20% had topical chemoprevention (mainly 5-fluorouracil cream) and 5% destructive therapies...IR strategies were variable within and between study centres (Figure 1) and were more frequently undertaken in patients with HR-CSCC or in those on azathioprine (p=0.01)...These data highlight the urgent need for prospective studies to identify optimal management of KTR following a first CSCC. Here we propose a risk stratification approach which may be used to guide use of prevention strategies."

Clinical • Basal Cell Carcinoma • Dermatology • Non-melanoma Skin Cancer • Oncology • Squamous Cell Carcinoma • Squamous Cell Skin Cancer • Transplantation

Management of Mycosis Fungoides and Sézary Syndrome With Oral Systemic Therapies. (PubMed, J Cutan Med Surg) - "FDA-approved oral therapies include bexarotene and vorinostat, both of which are effective in patients who are recalcitrant to prior topical therapies. Off-label oral therapies include methotrexate, acitretin, and chlorambucil...Chlorambucil is mainly used to treat erythrodermic MF. Investigational oral therapies for MF include tenalisib, duvelisib, cerdulatinib, lenalidomide, bortezomib, and azacytidine, and direct comparison studies between these investigational agents and FDA-approved therapies should be undertaken to better understand their role in the management of MF and SS."

Journal • Review • Cutaneous T-cell Lymphoma • Dermatology • Hematological Malignancies • Lymphoma • Mycosis Fungoides • Oncology • Sezary Syndrome • T Cell Non-Hodgkin Lymphoma

Systemic therapies for pediatric patients with ichthyosis (PubMed, Dermatologie (Heidelb)) - "Acitretin is currently the only approved systemic therapy. Pathophysiologically driven and therefore personalized and targeted therapies, in the form of topical replacement proteins or lipids, small molecules with a variety of target structures and biologics to address inflammation, are the focus of new therapeutic options. Causal therapeutic approaches, such as gene therapies, are currently under development."

Journal • Review • Atopic Dermatitis • Dermatitis • Dermatology • Dermatopathology • Gene Therapies • Immunology • Inflammation • Pediatrics • Vitiligo

Dissecting cellulitis of the scalp and HS: A retrospective study of 106 patients (AAD 2025) - "Highest treatment responses were seen for acitretin (4/4, 100%), IV antibiotics (ceftriaxone, vancomycin) (7/7, 100%), hormonal treatments (spironolactone (female), finasteride (male) (2/2, 100%)), ILK (49/51, 96.1%), biologics (adalimumab, infliximab, secukinumab) (15/17, 88.2%), and surgical excision (6/7, 85.7%). Isotretinoin had a mixed treatment response (14/27, 51.9%). 106 patients (91.5% male) were included with mean age 32.2 years old at symptom onset and 35.3 at diagnosis. Patients identified as Hispanic (47.2%), Black (19.8%), White (6.6%), Asian (6.6%), other/not specified (19.8%). Mean BMI was 34.2."

Retrospective data • Acne Vulgaris • Alopecia • Cardiovascular • CNS Disorders • Depression • Dermatology • Diabetes • Dyslipidemia • Hypertension • Immunology • Metabolic Disorders • Mood Disorders • Psychiatry

Adverse Effects and Risk of Skin Cancer Rebound in Patients Treated with Acitretin for Skin Cancer Prevention (AAD 2025) - "Acitretin for skin cancer prevention was well-tolerated although laboratory abnormalities, including elevated creatinine and decreased hemoglobin, were frequent findings. Discontinuation of acitretin did not lead to a significant rebound in cSCC incidence, suggesting that some patients treated with acitretin may be safely transitioned off therapy."

Adverse events • Clinical • Dermatology • Diabetes • Dyslipidemia • Genetic Disorders • Hypertriglyceridemia • Metabolic Disorders • Mucositis • Musculoskeletal Diseases • Musculoskeletal Pain • Non-melanoma Skin Cancer • Oncology • Pain • Pruritus • Skin Cancer • Squamous Cell Carcinoma • Squamous Cell Skin Cancer

Patient characteristics and treatment patterns in generalized pustular psoriasis (GPP): Real-world data from expanded access programs (EAPs) in Japan, China, and Argentina (AAD 2025) - "Ten patients used retinoids (acitretin); 50% (n=5/10) were either self-discontinued or discontinued due to lack of initial response or loss of response... This multinational real-world data set shows the chronic and heterogenous nature of GPP, with its high burden of flares and comorbidities (including patient-reported insomnia, suggesting psychological burden) [3]. Historical treatment patterns indicate high rates of discontinuation, highlighting the need for effective and long-term continuous treatment."

Clinical • Real-world • Real-world evidence • CNS Disorders • Dermatology • Immunology • Infectious Disease • Insomnia • Psoriasis • Pustular Psoriasis • Sleep Disorder • IL12A • IL17A • IL23A

A cross-sectional evaluation of dermatologist management strategies for lichen planus (AAD 2025) - "Clinicians in this cohort consistently opt for TCSs, TCIs, ILCs, and OIs. While these treatments have Class IA and IB evidence for their use in cutaneous LP, apart from OIs, other treatments with class I evidence, including acitretin, isotretinoin, and UVB, remain less frequently used.[4] This, coupled with a persistent knowledge gap regarding off-label medication use, highlights the need for LP treatment guidelines."

Dermatology • Dermatopathology • Lichen Planus

Navigating Treatment Challenges: Assessing Therapeutic Options for Verrucous Psoriasis (AAD 2025) - "Two patients were treated with apremilast, both displaying notable improvement in plaque size. Three patients received methotrexate, but only two showed partial improvement when it was combined with acitretin and high-dose corticosteroids. Eight patients were treated with biologics/systemic therapies, with the following partial improvement rates: adalimumab – 33% (n=1/3), etanercept - 50% (1/2), ixekizumab – 100% (n=1/1), ustekinumab – 100% (n=1/1), and infliximab 0% (n=0/1). No single regimen proved universally effective, highlighting the need for further research to identify more effective treatments for VP."

Dermatology • Immunology • Psoriasis

Rural-urban disparities in the use of targeted and non-targeted systemic medications for inflammatory dermatologic conditions: A DataDerm study (AAD 2025) - " Urban patients were more likely to receive any targeted systemic therapy (OR: 1.44, p0.05). Prescribing patterns of targeted and non-targeted systemic therapies for chronic inflammatory skin diseases highlight disparities between rural and urban communities, particularly among FDA-approved biologics and JAK inhibitors. Whether such disparities are due to barriers in accessing dermatologic care or other factors warrants further research (4)."

Atopic Dermatitis • Dermatitis • Dermatology • Hidradenitis Suppurativa • Immunology • Inflammation • Psoriasis

Revisiting Erosive Pustular Dermatosis: Case Series and the Need for Standardized Management (AAD 2025) - "Initial treatment typically involved topical corticosteroids and oral doxycycline. Refractory cases required more aggressive interventions, including oral acitretin, topical dapsone, zinc therapy, and trichloroacetic acid. EPD's variable presentation, treatment selection, and clinical response underscore the need for standardized diagnostic and therapeutic approaches. Developing a clinical grading system and follow-up protocols is essential for optimizing care and improving patient outcomes."

Clinical • Dermatology • Infectious Disease • Mood Disorders • Oncology • Pain • Pruritus • Squamous Cell Carcinoma

To test or not to test? Assessing the value of screening and monitoring tests among systemic oral treatments for psoriasis using an evidence-based approach (AAD 2025) - "This study assesses the need for screening and monitoring tests during deucravacitinib, apremilast, and acitretin treatments for psoriasis. The limited data available does not support a requirement to conduct extensive laboratory monitoring but also does not prove that more extensive laboratory testing should not be done. Thus, good judgment is needed by clinicians."

Cardiovascular • CNS Disorders • Congestive Heart Failure • Depression • Dermatology • Dyslipidemia • Gastroenterology • Gastrointestinal Disorder • Heart Failure • Hepatitis B • Hepatology • Hypertriglyceridemia • Immunology • Infectious Disease • Inflammatory Bowel Disease • Novel Coronavirus Disease • Oncology • Psoriasis • Psychiatry • Respiratory Diseases • Tuberculosis